Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 102.75 -2.35% -2.47
ALXN closed down 2.35 percent on Wednesday, August 5, 2020, on 64 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ALXN trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Outside Day Range Expansion 0.00%
200 DMA Support Bullish -2.35%
Bollinger Band Squeeze Range Contraction -2.35%
BB Squeeze Started Range Contraction -2.35%
Crossed Above 200 DMA Bullish -2.00%
Fell Below 200 DMA Bearish 0.25%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Medicine Biopharmaceutical Medical Specialties Organ Systems Healthcare Providers Metabolic Disorders Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Inflammatory Disorders Myasthenia Gravis Alexion Pharmaceuticals Atypical Hemolytic Uremic Syndrome Blood Disorders Genetic Disease Hemolytic Uremic Syndrome Kidney Transplant Renal Transplant

Is ALXN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 125.52
52 Week Low 72.67
Average Volume 1,961,799
200-Day Moving Average 104.62
50-Day Moving Average 110.93
20-Day Moving Average 106.41
10-Day Moving Average 104.31
Average True Range 3.25
ADX 19.87
+DI 16.63
-DI 26.54
Chandelier Exit (Long, 3 ATRs ) 103.70
Chandelier Exit (Short, 3 ATRs ) 110.57
Upper Bollinger Band 111.55
Lower Bollinger Band 101.27
Percent B (%b) 0.14
BandWidth 9.66
MACD Line -1.86
MACD Signal Line -1.67
MACD Histogram -0.1892
Fundamentals Value
Market Cap 22.94 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 44.48
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 107.87
Resistance 3 (R3) 108.27 106.97 107.01
Resistance 2 (R2) 106.97 105.67 106.77 106.73
Resistance 1 (R1) 104.86 104.86 104.21 104.46 106.44
Pivot Point 103.56 103.56 103.24 103.36 103.56
Support 1 (S1) 101.45 102.26 100.80 101.05 99.06
Support 2 (S2) 100.15 101.45 99.95 98.77
Support 3 (S3) 98.04 100.15 98.49
Support 4 (S4) 97.64